和鉑醫藥-B(02142.HK)與丹娜-法伯癌症研究院訂立研究合作協議 以共同開發癌症治療新型生物療法
格隆匯6月16日丨和鉑醫藥-B(02142.HK)公佈,公司已與丹娜-法伯癌症研究院訂立一項為期多年、涉及多方面的研究合作協議,以共同開發癌症治療的新型生物療法。
公司科學家與丹娜-法伯研究者將共同開發新型腫瘤藥物,包括雙特異性抗體及CAR-T細胞產品。近年來,雙特異性抗體及CAR-T細胞療法均被視為腫瘤免疫學領域的新一代解決方案。雙特異性抗體因具有結合兩種不同靶標的能力,可望擴展單克隆抗體(mAb)療法的可能性,而CAR-T細胞療法為一種創新的免疫療法,使用經特別重組的T細胞,將其重新定向以靶向癌細胞。
此一戰略合作將利用公司的轉基因Harbour Mice平台與丹娜-法伯在CAR-T細胞發育及基礎腫瘤學研究方面的專業知識,以促成新型生物療法。
公司的抗體技術平台Harbour Mice以兩個自有轉基因小鼠平台為基礎,將用於促成可供人體治療的抗體。該平台具有廣大的潛力,可望促成常規的新一代生物製劑,例如全人源、親和力成熟並具出色可溶性及可開發性的雙特異性及多特異性、CAR-T或VH結構域衍生產品。
據悉,丹娜-法伯癌症研究院為哈佛醫學院的附屬醫院。丹娜-法伯致力於為癌症患者提供當今可得的最佳癌症護理,同時通過深入的基礎及臨牀研究促進未來的治療方法。其為發展國家癌症治療方針以及提升癌症護理質量及功效的領導者。其具有獨特的跨學科、富同理心及合作式照護的模式,在整體療程中以患者及其家人為中心。其專業領域包括乳癌、皮膚癌、婦癌、肺癌、幹細胞移植及癌症臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.